The biomarker CA19-9 may promote pancreatic disease and cancer. This unexpected result – CA19-9 was thought to be benign until now – comes from researchers in the US, Germany and France who studied genetically engineered mice and organoid models of pancreatic disease. The finding, which is reported in Science, could help in the development of new treatments for pancreatic cancer, which is one of the deadliest human cancers.
“By understanding whether and how CA19-9 contributes to disease, we are now poised to apply this knowledge to improve the utility of CA19-9 both as a biomarker, but also as a new treatment strategy,” says study lead author Danielle Engle of the Cold Spring Harbor Laboratory.
The French researchers involved in this work are from the Cochin Institute in Paris.
Read the research paper: The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice. D.D. Engle et al., Science 10.1126/science.aaw3145.